Tests a home care team for people with Parkinson disease
Tests a specialized home team for adults with moderate to severe Parkinson disease.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- Bordeaux, Lille, Limoges, and Poitiers, FranceSee the 4 sites
- Trial code
- Registry title
- Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 6 Dec 2022
- Expected to end
- 6 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- ESPark Intervention
- Record updated
- 23 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with idiopathic Parkinson's disease at a more advanced stage who live at home with a family or friend caregiver. It tests a specialized home care team.
- Age
- Patients and caregivers: over 18 years
- Sex
- All
- Disease stage
- Idiopathic Parkinson's disease, Hoehn and Yahr Stage greater than or equal to 3, without major cognitive impairment (MOCA score ≥21)
Main reasons for not taking part
- Dementia or severe confusion that affects understanding
- Living in an institution or foster care, or a move or institutionalization planned within 6 months
- Already in another non-drug management trial
- Severe and unstable illness that does not allow follow-up
- No available non-professional primary caregiver, or a caregiver who cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- For the patient:
- Patient with a diagnosis of idiopathic Parkinson's disease
- Patient over 18 years
- Patient with a Hoehn and Yahr Stage greater than or equal to 3
- Patient without major cognitive impairment defined by a MOCA score ≥21
- Patient living at home
- Patient with an identified non-professional primary caregiver
- Person affiliated with or benefiting from a social security plan
- Free, informed and and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research); For the caregiver:
- Male or female over 18 years
- Able to respond to research interviews/questionnaires
- Free, informed and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research)
Who cannot take part
- Patients already included in another non-drug management trial
- Patient with medically indicated dementia impairing comprehension and adherence, and/or with severe confusion or psycho-hallucinatory state
- Presence of a primary caregiver with a known severe and unstable disease that does not allow for the conduct of the study
- Presence of a primary caregiver with a known cognitive or psychiatric disorder (chronic progressive psychosis) that does not allow for the proper conduct of the study
- Primary caregiver with a known severe and unstable illness that does not allow for the proper conduct of the study
- Primary caregiver with known cognitive or psychiatric disorders (chronic progressive psychosis) that do not allow the study to be conducted properly
- For the patient:
- Institutionalized or foster care patients
- Patients with a known severe and unstable general pathology that does not allow for patient follow-up
- Patients whose institutionalization is envisaged in the short term (within 6 months) or for whom a change of residence is envisaged in the short term and would not allow for follow-up assessments
- Patients under guardianship or unable to express consent
- Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up
- Pregnant or breastfeeding woman; For the caregiver:
- Unable to follow the research interviews or questionnaires
- Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up
Where in France
- Hopital PellegrinBordeaux, FranceContact: Alexandra FOUBERT-SAMIER, DrTaking people
- CHU de LilleLille, FranceContact: Nicolas CARRIERE, DrTaking people
- CHU de LimogesLimoges, FranceContact: Jean-Luc HOUETO, PrTaking people
- CHU PoitiersPoitiers, FranceContact: Isabelle BENATRU, DrTaking people
About the trial
What the trial wants to find out
A pilot experiment interventional study is proposed in order to set up multidisciplinary team for Parkinson's patients at home. The aim of this study is to evaluate the effectiveness of this specialized Parkinson's team (ESPark) intervention a on the quality of life of patients with moderate to severe Parkinson's disease
The 2 groups in the trial
- Standard careNo study treatment, for comparison
- ESPark InterventionTreatment being tested
Under medical prescription and in addition to medical and physiotherapy care, the ESPark will intervene in an ecological way with Parkinson's patients in order to rehabilitate them, maintain their autonomy in their daily life and their social life with the aim of improving the quality of life of the patient and his main caregiver. Beyond a rehabilitative intervention in the home, the ESPark's mission would also be to optimize the patient's living environment and possibly help with the implementation of the necessary aids in the continuity of medical care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Effectiveness of the Parkinson's Specialized Teams Intervention on the Quality of Life of Parkinson's Patients in the Territory of the Nouvelle-Aquitaine and Hauts-de-France: ES-Park Pilot Study.
- Plain-language title
- Tests a home care team for people with Parkinson diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 July 2025